Dr. Simon Lowry serves as Chief Medical Officer and Head of Research and Development at Emergent BioSolutions Inc., where he leads the company's global clinical development, regulatory strategy, and medical affairs efforts. With over 25 years of experience in the biopharmaceutical industry, Dr. Lowry is a seasoned physician specializing in infectious diseases. He earned his medical degree from the University of London and completed specialty training in infectious diseases and general medicine at leading UK institutions, including St. Bartholomew's Hospital. Prior to joining Emergent in 2021, Dr. Lowry held senior leadership roles at GlaxoSmithKline (GSK), where he advanced from Vice President of Infectious Diseases Clinical Development to Therapeutic Area Head for Vaccines. At GSK, he oversaw the development of multiple late-stage vaccine candidates, including programs for respiratory syncytial virus (RSV), Ebola, and shingles, contributing to several regulatory approvals and global health initiatives. His tenure also included strategic oversight of partnerships with organizations like the Bill & Melinda Gates Foundation, driving innovations in pandemic preparedness. At Emergent BioSolutions, Dr. Lowry directs a robust R&D pipeline focused on biodefense and public health threats, including next-generation vaccines for COVID-19, Ebola, and anthrax. Under his leadership, the company has accelerated manufacturing scale-up for emergency-use countermeasures and advanced clinical trials for novel therapeutics. His expertise continues to position Emergent at the forefront of rapid-response biopharma solutions, emphasizing agility and innovation in addressing global health security challenges.